Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] V2-specific antibodies in HIV-1 vaccine research and natural infection: controllers or surrogate markers
R Duerr, MK Gorny - Vaccines, 2019 - mdpi.com
Most human immunodeficiency virus (HIV) vaccine trials have lacked efficacy and empirical
vaccine lead targets are scarce. Thus far, the only independent correlate of reduced risk of …
vaccine lead targets are scarce. Thus far, the only independent correlate of reduced risk of …
Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response
Systemic vaccination of macaques with V1-deleted (ΔV1) envelope immunogens reduce the
risk of SIVmac251 acquisition by approximately 60%, with protective roles played by V2 …
risk of SIVmac251 acquisition by approximately 60%, with protective roles played by V2 …
Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIVmac251 acquisition in macaques
Introduction An efficacious HIV vaccine will need to elicit a complex package of innate,
humoral, and cellular immune responses. This complex package of responses to vaccine …
humoral, and cellular immune responses. This complex package of responses to vaccine …
A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1
A productive HIV-1 infection in humans is often established by transmission and propagation
of a single transmitted/founder (T/F) virus, which then evolves into a complex mixture of …
of a single transmitted/founder (T/F) virus, which then evolves into a complex mixture of …
Priming with DNA expressing trimeric HIV V1V2 alters the immune hierarchy favoring the development of V2-specific antibodies in rhesus macaques
The RV144 vaccine trial revealed a correlation between reduced risk of HIV infection and
the level of nonneutralizing-antibody (Ab) responses targeting specific epitopes in the …
the level of nonneutralizing-antibody (Ab) responses targeting specific epitopes in the …
Characterization of envelope sequence of HIV virus in children infected with HIV in Vietnam
Background: HIV is characterized by high levels of genetic variability, including increased
numbers of heterogeneous sequences of the envelope region. Therefore, studying genetic …
numbers of heterogeneous sequences of the envelope region. Therefore, studying genetic …
[HTML][HTML] Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity
Antibodies against the HIV-1 V1V2 loops were the only correlate of reduced infection risk in
the RV144 vaccine trial, highlighting the V1V2 loops as promising targets for vaccine design …
the RV144 vaccine trial, highlighting the V1V2 loops as promising targets for vaccine design …
A genetic shift in an escaped transmitted/founder virus guides combinatorial vaccine design against HIV-1
A productive HIV-1 infection is often established by a single transmitted/founder (T/F) virus,
which then evolves into a complex mixture of variants during the lifetime of infection. An …
which then evolves into a complex mixture of variants during the lifetime of infection. An …
Correction: Trinh, HV, et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365
Correction: Trinh, HV, et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai
Early Acute Infection Cohort. Cells 2019, 8, 365 Next Article in Journal An Effective Primary …
Early Acute Infection Cohort. Cells 2019, 8, 365 Next Article in Journal An Effective Primary …
[کتاب][B] Design of HIV-1 Vaccine Guided by Mechanisms of Immune-Escape by Acute Viruses
S Jain - 2020 - search.proquest.com
HIV-1 continues to be a public health concern, causing 1.8 million new infections per year
globally. Despite four decades of research around the globe, an effective HIV-1 vaccine is …
globally. Despite four decades of research around the globe, an effective HIV-1 vaccine is …